Agios Pharma (AGIO) Reports Q2 Loss Per Share of 85c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Agios Reports Second Quarter 2015 Financial Results and Provides Updates on Clinical Development Progress
August 6, 2015 7:30 AM EDTGlobal Phase 3 Registration-enabling Studies on Track to Begin in Second Half of 2015 for AG-221 & First Half of 2016 for AG-120
Phase 1 Expansion Studies for AG-221 & AG-120 Programs Ongoing
CAMBRIDGE, Mass., Aug. 6, 2015 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals (NASDAQ: AGIO), a leader in the fields of cancer metabolism and rare genetic metabolic disorders, today reported business highlights and financial results for the second quarter ended June 30, 2015.
"In the first half of 2015, we continued to drive rapid and meaningful progress across our development... More
